IKAROVEC
Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
IKAROVEC
Industry:
Biotechnology Health Care Life Science
Founded:
2018-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Total Funding:
2.5 M GBP
Similar Organizations
ATAI Life Sciences
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Founder
Investors List
UK Innovation & Science Seed Fund
UK Innovation & Science Seed Fund investment in Seed Round - Ikarovec
Future Planet Capital
Future Planet Capital investment in Seed Round - Ikarovec
LifeArc
LifeArc investment in Seed Round - Ikarovec
Parkwalk Advisors
Parkwalk Advisors investment in Seed Round - Ikarovec
More informations about "Ikarovec"
About Us - Ikarovec
Ikarovec - Crunchbase Company Profile & Funding
Ikarovec is developing novel gene therapies to treat major ophthalmic indications. Where is Ikarovec's headquarters? Ikarovec is located in Cambridge, Cambridgeshire, United Kingdom. Who invested in Ikarovec? Ikarovec has 5 …See details»
Member profile: Ikarovec Limited | BIA - bioindustry.org
Ikarovec is a gene therapy company based on the Norwich Research Park (NRP) with a pipeline of novel, bi-cistronic AAV-based gene therapies to treat the unmet clinical needs of serious but …See details»
Norwich Research Park start-up Ikarovec sets its sight …
The Ikarovec team at the Norwich Research Park (L to R – Dr Laura Vaux, Dr Andy Osborne, Dr Emily Warner, Dr Katie Binley). Ikarovec is a pioneering gene therapy start-up, based at Norwich Research Park, that is committed to the …See details»
Ikarovec set to initiate the next phase of development for their …
Jun 1, 2023 Norwich, Stevenage, UK and Laupheim, Germany, June 1, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization …See details»
Ikarovec’s seed round extension brings total to £8 million with ...
Ikarovec’s seed round extension brings total to £8 million with proceeds to advance lead sight loss programme towards clinic. Norwich, UK, October 23 2024 – Ikarovec, which is developing …See details»
Meet a researcher at Ikarovec - Norwich Research Park
Apr 24, 2023 Established in 2020, Ikarovec creates novel gene therapies designed to counter the effects of highly prevalent diseases which cause millions of people each year to go blind. Our lead programme is focused on treating …See details»
Ikarovec - Colney, United Kingdom - bionity.com
Jun 6, 2023 About Ikarovec Established in 2018, Ikarovec is developing novel, differentiated gene therapies for major ophthalmic indications. Its lead product, a bicistronic gene therapy for …See details»
Ikarovec Announce £5M in new funding - Norwich Research Park
Oct 28, 2024 Ikarovec would like to thank its investors for their continued support to enable us to do this and to advance our pipeline of gene therapies for major eye diseases.’ Dr David Guyer, …See details»
Rentschler Biopharma, Ikarovec Collaboration Set to Speed
Jun 1, 2023 A collaboration between global contract development and manufacturing organization (CDMO), Rentschler Biopharma, and pre-clinical-phase gene therapy company, …See details»
Rentschler Biopharma joins forces with Ikarovec to - GlobeNewswire
Jun 1, 2023 Ikarovec is developing novel gene therapies to treat serious, but common eye diseases ... Rentschler Biopharma SE, a leading global contract development and …See details»
Ikarovec Company Profile 2024: Valuation, Funding & Investors
Ikarovec General Information Description. Operator of a gene therapy company intended to treat common eye diseases. The company targets multiple disease targets and pathways that help …See details»
News - Ikarovec
Ikarovec scientific team presented three poster and one oral communication at the Denver Association for Research in Vision and Ophthalmology (ARVO) conference, between 1st and …See details»
Ikarovec - seed funding round closes at £8m - Parkwalk Advisors
Oct 23, 2024 Ikarovec is a biotech gene therapy company with a focus on ophthalmology. Norwich, UK, October 2024 – Ikarovec, which is developing novel bicistronic gene therapies …See details»
Ikarovec - Company Profile - Tracxn
Ikarovec - Developer of gene therapies for ophthalmic treatment. Raised a total funding of $3.24M over 2 rounds from 8 investors. Valued at $4.78M. Founded by Peter Widdowson and Robert …See details»
Rentschler Biopharma joins forces with Ikarovec to ... - BioSpace
Jun 1, 2023 Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal …See details»
Ophthalmic gene therapy company Ikarovec launches with £2.5m …
Feb 5, 2020 Ikarovec was founded in 2019 by Chief Scientific Officer Dr Peter Widdowson, around intellectual property spun out of Quethera, which he founded and was bought by …See details»
Ikarovec - VentureRadar
Ikarovec is developing novel, differentiated gene therapies for major ophthalmic indications. Its lead product, a multicistronic gene therapy for diabetic macular edema, is in preclinical …See details»
IKC-159V - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»